135 related articles for article (PubMed ID: 28875839)
1. Repositioning Drugs for Rare Immune Diseases: Hopes and Challenges for a Precision Medicine.
Valencic E; Smid A; Jakopin Z; Tommasini A; Mlinaric-Rascan I
Curr Med Chem; 2018; 25(24):2764-2782. PubMed ID: 28875839
[TBL] [Abstract][Full Text] [Related]
2. Computational drug repositioning for rare diseases in the era of precision medicine.
Delavan B; Roberts R; Huang R; Bao W; Tong W; Liu Z
Drug Discov Today; 2018 Feb; 23(2):382-394. PubMed ID: 29055182
[TBL] [Abstract][Full Text] [Related]
3. Inferring new indications for approved drugs via random walk on drug-disease heterogenous networks.
Liu H; Song Y; Guan J; Luo L; Zhuang Z
BMC Bioinformatics; 2016 Dec; 17(Suppl 17):539. PubMed ID: 28155639
[TBL] [Abstract][Full Text] [Related]
4. Rilonacept--CAPS and beyond.
Stahl N; Radin A; Mellis S
Ann N Y Acad Sci; 2009 Dec; 1182():124-34. PubMed ID: 20074281
[TBL] [Abstract][Full Text] [Related]
5. A survey of current trends in computational drug repositioning.
Li J; Zheng S; Chen B; Butte AJ; Swamidass SJ; Lu Z
Brief Bioinform; 2016 Jan; 17(1):2-12. PubMed ID: 25832646
[TBL] [Abstract][Full Text] [Related]
6. Computational and experimental advances in drug repositioning for accelerated therapeutic stratification.
Shameer K; Readhead B; Dudley JT
Curr Top Med Chem; 2015; 15(1):5-20. PubMed ID: 25579574
[TBL] [Abstract][Full Text] [Related]
7. Bridging the gap between the clinician and the patient with cryopyrin-associated periodic syndromes.
Cantarini L; Lucherini OM; Frediani B; Brizi MG; Bartolomei B; Cimaz R; Galeazzi M; Rigante D
Int J Immunopathol Pharmacol; 2011; 24(4):827-36. PubMed ID: 22230390
[TBL] [Abstract][Full Text] [Related]
8. Cryopyrin-associated periodic syndromes: background and therapeutics.
Kubota T; Koike R
Mod Rheumatol; 2010 Jun; 20(3):213-21. PubMed ID: 20140476
[TBL] [Abstract][Full Text] [Related]
9. Target-Based Drug Repositioning Using Large-Scale Chemical-Protein Interactome Data.
Sawada R; Iwata H; Mizutani S; Yamanishi Y
J Chem Inf Model; 2015 Dec; 55(12):2717-30. PubMed ID: 26580494
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory pathway network-based drug repositioning and molecular phenomics.
Gu J; Crosier PS; Hall CJ; Chen L; Xu X
Mol Biosyst; 2016 Aug; 12(9):2777-84. PubMed ID: 27345454
[TBL] [Abstract][Full Text] [Related]
11. Successful Treatment of CINCA/NOMID Syndrome with Interleukin-1 Blockade.
Macejová Z; Vargová V; Matejka M; Szekanecz Z
Isr Med Assoc J; 2015 Jun; 17(6):389-91. PubMed ID: 26234003
[No Abstract] [Full Text] [Related]
12. Pharmacological treatment options for cryopyrin-associated periodic syndromes.
Landmann EC; Walker UA
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):855-864. PubMed ID: 28586272
[TBL] [Abstract][Full Text] [Related]
13. [CAPS treatment].
Jiménez Treviño S; Ramos Polo E
Med Clin (Barc); 2011 Jan; 136 Suppl 1():29-33. PubMed ID: 21596184
[TBL] [Abstract][Full Text] [Related]
14. Drug repositioning for personalized medicine.
Li YY; Jones SJ
Genome Med; 2012; 4(3):27. PubMed ID: 22494857
[TBL] [Abstract][Full Text] [Related]
15. Drug repositioning: re-investigating existing drugs for new therapeutic indications.
Padhy BM; Gupta YK
J Postgrad Med; 2011; 57(2):153-60. PubMed ID: 21654146
[TBL] [Abstract][Full Text] [Related]
16. Treatment of autoinflammatory syndromes.
Gattorno M; Martini A
Curr Opin Pediatr; 2010 Dec; 22(6):771-8. PubMed ID: 20966753
[TBL] [Abstract][Full Text] [Related]
17. Exanthem with cryopyrin associated periodic syndromes and consideration of IL-1 targeted therapy for neutrophilic predominant urticaria.
Wanderer AA; Kambe N; Nakamura Y
Allergol Int; 2010 Sep; 59(3):321-322. PubMed ID: 20657165
[No Abstract] [Full Text] [Related]
18. Drug repositioning by structure-based virtual screening.
Ma DL; Chan DS; Leung CH
Chem Soc Rev; 2013 Mar; 42(5):2130-41. PubMed ID: 23288298
[TBL] [Abstract][Full Text] [Related]
19. [Indications and modes of use for interleukin (IL)-1 antagonists in inflammatory dermatosis: a new therapeutic approach to immune-mediated inflammatory diseases].
Lipsker D; Lenormand C
Ann Dermatol Venereol; 2012 Jun; 139(6-7):459-67. PubMed ID: 22721478
[TBL] [Abstract][Full Text] [Related]
20. [Pathophysiological mechanisms underlying cryopyrin-associated periodic syndromes: genetic and molecular basis and the inflammasome].
Aróstegui JI
Med Clin (Barc); 2011 Jan; 136 Suppl 1():22-8. PubMed ID: 21596183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
